{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:21:54Z","timestamp":1773019314545,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite improved outcomes in children with leukemia, complications such as osteonecrosis are common. We conducted a systematic review to investigate the role of bisphosphonates in reducing pain, improving mobility, and stabilizing lesions in pediatric leukemia survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we searched the PubMed, Embase, Cochrane, Web of Science, Scopus, CINAHL, and ClinicalTrials.gov databases. Five of 221 articles retrieved met our inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Bisphosphonates, especially when combined with dietary calcium and vitamin D supplements and physical therapy (supplements\/PT) were associated with improved pain and mobility in 54% and 50% of patients, respectively. A significantly greater proportion of patients treated with bisphosphonates (83%) reported mild\/moderate pain or no pain compared with those with supplements\/PT alone (36%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Sixty-six percent of patients treated with bisphosphonates achieved improved\/full mobility compared with 27% of those treated with supplements\/PT alone (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.02). However, 46% of patients showed progressive joint destruction despite bisphosphonate therapy. No adverse events were reported, except for acute phase reactions to intravenous therapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Bisphosphonates, when combined with supplements\/PT, were associated with less pain and improved mobility, but not prevention of joint destruction in pediatric leukemia patients with osteonecrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000001793","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T04:14:57Z","timestamp":1587615297000},"page":"e365-e370","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Bisphosphonate Therapy for Treating Osteonecrosis in Pediatric Leukemia Patients: A Systematic Review"],"prefix":"10.1097","volume":"43","author":[{"given":"Shanaz M.","family":"Daneshdoost","sequence":"first","affiliation":[{"name":"Orthopaedic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jad M.","family":"El Abiad","sequence":"additional","affiliation":[{"name":"Orthopaedic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy J.","family":"Ruble","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne C.","family":"Jones","sequence":"additional","affiliation":[{"name":"Orthopaedic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet L.","family":"Crane","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol D.","family":"Morris","sequence":"additional","affiliation":[{"name":"Orthopaedic Surgery"},{"name":"Oncology, The Johns Hopkins University, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Levin","sequence":"additional","affiliation":[{"name":"Orthopaedic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"R2-20250804","first-page":"83","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2000.18.18.3262","article-title":"Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children\u2019s Cancer Group","volume":"18","author":"Mattano","year":"2000","journal-title":"J Clin Oncol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"e27300","DOI":"10.1002\/pbc.27300","article-title":"Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia","volume":"65","author":"Mogensen","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1097-0142(19900415)65:8<1717::AID-CNCR2820650809>3.0.CO;2-B","article-title":"Osteonecrosis in pediatric patients with acute lymphoblastic leukemia","volume":"65","author":"Murphy","year":"1990","journal-title":"Cancer"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.leu.2405032","article-title":"High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis","volume":"22","author":"Patel","year":"2008","journal-title":"Leukemia"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2011.37.3217","article-title":"Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia","volume":"29","author":"Te Winkel","year":"2011","journal-title":"J Clin Oncol"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2006.07.9947","article-title":"Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma","volume":"25","author":"Karimova","year":"2007","journal-title":"J Clin Oncol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mph.0000163215.37147.13","article-title":"Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: a 13-year longitudinal observational study","volume":"27","author":"Lackner","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1302\/0301-620X.73B1.1991778","article-title":"Natural history of nontraumatic avascular necrosis of the femoral head","volume":"73","author":"Ohzono","year":"1991","journal-title":"J Bone Joint Surg Br"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2006.06.2539","article-title":"High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia","volume":"25","author":"Niinimaki","year":"2007","journal-title":"J Clin Oncol"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/pbc.22428","article-title":"Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL)","volume":"54","author":"Kotecha","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/pbc.24313","article-title":"Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia","volume":"60","author":"Leblicq","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1515\/JPEM.2006.19.2.161","article-title":"Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia\u2014two-year outcomes","volume":"19","author":"Nguyen","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/cam4.645","article-title":"Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL)","volume":"5","author":"Padhye","year":"2016","journal-title":"Cancer Med"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/pbc.24563","article-title":"Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis","volume":"60","author":"Padhye","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-2003-45495","article-title":"Joint preserving surgery for osteonecrosis and osteochondral defects after chemotherapy in childhood","volume":"215","author":"Werner","year":"2003","journal-title":"Klin Padiatr"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1302\/0301-620X.91B8.21518","article-title":"The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years","volume":"91","author":"Agarwala","year":"2009","journal-title":"J Bone Joint Surg Br"},{"key":"R19-20250804","first-page":"2155","article-title":"The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study","volume":"87","author":"Lai","year":"2005","journal-title":"J Bone Joint Surg Am"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"206132","DOI":"10.1155\/2010\/206132","article-title":"Short-term bisphosphonate therapy could ameliorate osteonecrosis: a complication in childhood hematologic malignancies","volume":"2010","author":"Greggio","year":"2010","journal-title":"Case Rep Med"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bone.2013.09.023","article-title":"Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review","volume":"58","author":"Eriksen","year":"2014","journal-title":"Bone"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis","volume":"142","author":"Tella","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bone.2009.04.255","article-title":"Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease","volume":"45","author":"Johannesen","year":"2009","journal-title":"Bone"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/17453674.2012.729184","article-title":"Treatment of spontaneous osteonecrosis of the knee (SPONK) by a bisphosphonate","volume":"83","author":"Jureus","year":"2012","journal-title":"Acta Orthop"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00167-010-1106-4","article-title":"Possible beneficial effect of bisphosphonates in osteonecrosis of the knee","volume":"18","author":"Kraenzlin","year":"2010","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1172\/JCI121561","article-title":"Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain","volume":"129","author":"Zhu","year":"2019","journal-title":"J Clin Invest"},{"key":"R27-20250804","first-page":"825","article-title":"Bisphosphonates-induced osteonecrosis of the jaw\u2014epidemiological, clinical and histopathological aspects","volume":"59","author":"Manea","year":"2018","journal-title":"Rom J Morphol Embryol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:09:53Z","timestamp":1754338193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001793","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737826634.793586071","asserted-by":"object"}]},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-08-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}